Drug intelligence / Profile preview

NWPT-SM32300

Development stage
Phase 1
Lead developer
NW PharmaTech
Modality
Small Molecules
Administration
Oral
01

Overview

NWPT-SM32300 is an investigational, pharmaceutical-grade oral cannabidiol (CBD) formulation developed by NW-Pharmatech. It utilizes a high-loading micellar delivery system formulated as a softgel capsule to improve the oral bioavailability and absorption consistency of CBD. NWPT-SM32300 is under clinical development as a monotherapy for the treatment of acute schizophrenia and clinical high risk for psychosis (CHR-P). Unlike traditional antipsychotics that primarily target dopamine D2 receptors, CBD acts through a multi-target mechanism of action, including negative allosteric modulation of cannabinoid receptors (CB1 and CB2), agonism of serotonin 5-HT1A and TRPV1 receptors, antagonism of GPR55, and inhibition of fatty acid amide hydrolase (FAAH) to enhance endocannabinoid signaling.

Other names
CBDcannabidiol
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on NWPT-SM32300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWPT-SM32300.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call